Show simple item record

dc.contributor.authorBarcelos, Samantha Thifani Alrutzpt_BR
dc.contributor.authorSperb, Amanda Souza Silvapt_BR
dc.contributor.authorMoraes, Helena Abadiept_BR
dc.contributor.authorLongo, Larissept_BR
dc.contributor.authorMoura, Bruna Concheski dept_BR
dc.contributor.authorMichalczuk, Matheus Truccolopt_BR
dc.contributor.authorCruz, Carolina Uribept_BR
dc.contributor.authorCerski, Carlos Thadeu Schmidtpt_BR
dc.contributor.authorSilveira, Themis Reverbel dapt_BR
dc.contributor.authorDall'Alba, Valescapt_BR
dc.contributor.authorÁlvares-da-Silva, Mário Reispt_BR
dc.date.accessioned2023-03-10T03:27:12Zpt_BR
dc.date.issued2022pt_BR
dc.identifier.issn1665-2681pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/255562pt_BR
dc.description.abstractIntroduction and objectives: Cardiovascular disease (CVD) is the major cause of death in non-alcoholic fatty liver disease (NAFLD), a clinical condition without any approved pharmacological therapy. Probiotics are often indicated for the disease, but their results are controversial in part due to the poor quality of studies. Thus, we investigated the impact of 24-week probiotics supplementation on cardiovascular risk (CVR) in biopsy-proven non-alcoholic steatohepatitis (NASH) patients. Patients and methods: Double-blind, placebo-controlled, single-center study (NCT03467282), adult NASH, randomized for 24 weeks daily sachets of probiotic mix (109CFU of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei and Bifidobacterium lactis) or placebo. Clinical scores (atherogenic indexes, atherosclerotic cardiovascular disease-ASCVD and systematic coronary risk evaluation-SCORE), biochemistry, miR-122, miR-33a, plasminogen activator inhibitor-1 (PAI-1), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), were determined before and after the intervention. Results: Forty-six patients were enrolled (23 received probiotics and 23 placebo), with a mean age of 51.7 years, most of them females and whites. Clinical and demographic features were similar between the groups at the baseline. The Median NAFLD activity score was 4.13 in both groups. Fibrosis was mild in most patients (15.2% and 65.2% F0 and F1, respectively). Treatment did not promote any clinically significant changes in body mass index or laboratory, including lipid and glucose profile. High CVR patients through atherogenic indexes decreased from baseline in both groups, as well as PAI-1 and miR-122 levels, although there was no difference between probiotics and placebo. Conclusions: A 24-week probiotic mix administration was not superior to placebo in reducing CVR markers in patients with NASH.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofAnnals of hepatology. México. Vol. 28 (2022), 100769, 8 p.pt_BR
dc.rightsOpen Accessen
dc.subjectFatores de risco de doenças cardíacaspt_BR
dc.subjectCardiovascular risken
dc.subjectClinical trialen
dc.subjectMicroRNAspt_BR
dc.subjectHepatopatia gordurosa não alcoólicapt_BR
dc.subjectNon-alcoholic fatty liver diseaseen
dc.subjectProbioticsen
dc.subjectProbióticospt_BR
dc.titleOral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH : a double-blind placebo-controlled randomized studypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001161832pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record